Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06672068 | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | not yet recruiting | Phase 2 | 60 | TYK Medicines, IncINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06752382 | Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752408 | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer(ANOTHER) | not yet recruiting | Phase 2 | 316 | Peking Union Medical College HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748508 | Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer(FDZL-GC003) | not yet recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750848 | Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer | not yet recruiting | Phase 2 | 48 | Jundong WuOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06750952 | Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial(iTHYM) | not yet recruiting | Phase 2 | 24 | Sun Yat-sen UniversityOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06751277 | QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer | not yet recruiting | Phase 2 | 26 | xiang yangOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06751394 | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer(TRACER) | not yet recruiting | Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746545 | A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer. | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06744894 | SIL as Maintenance Therapy in Multiple Myeloma | not yet recruiting | Phase 2 | 50 | Navy General Hospital, BeijingOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | not yet recruiting | Phase 2 | 63 | Peking UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06739317 | SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 398 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06584071 | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | not yet recruiting | Phase 1 / Phase 2 | 140 | Biotheus Inc.INDUSTRY | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06654947 | A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06733233 | A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer | not yet recruiting | Phase 2 | 23 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Dec 13, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06731153 | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | not yet recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer | not yet recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714266 | Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06706895 | A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer | not yet recruiting | Phase 2 | 21 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT06704828 | A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors | not yet recruiting | Phase 2 | 20 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06700603 | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Rui-hua Xu, MD, PhDOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06701344 | Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients(GOAL) | not yet recruiting | Phase 2 | 7 | Ruijin HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06699459 | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC(NICRRBTC) | not yet recruiting | Phase 2 | 76 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699498 | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06697366 | Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer | not yet recruiting | Phase 2 | 27 | Ruijin HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | not yet recruiting | Phase 2 | 49 | Fudan UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06694350 | Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC | not yet recruiting | Phase 2 | 54 | Zhejiang Provincial People's HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06692491 | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS(SPRING) | not yet recruiting | Phase 2 | 200 | Peking University Shenzhen HospitalOTHER | 0 | Nov 18, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06643689 | Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms(TAPES) | not yet recruiting | Phase 2 | 394 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06688656 | Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC(Peri-E) | not yet recruiting | Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681285 | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)(CAR-RMEC) | not yet recruiting | Phase 2 | 51 | Hebei Medical University Fourth HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | not yet recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Dec 30, 2024source: clinicaltrials